36 withdrawn. 36 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Withdrawn 36 |
| Phase 1 | 11 | Withdrawn 11 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma R-DHAP, Pola-R-DHAP - Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 | Withdrawn | Fondazione Italiana Linfomi - ETS | 2024-01-01 | 2024-05-21 | |
| A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies STI-3031 - Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Withdrawn | Sorrento Therapeutics, Inc. | 2023-03-01 | 2023-05-01 | |
| Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant loncastuximab tesirine - Relapsed Diffuse Large B-cell Lymphoma | Phase 2 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2022-04-08 | 2023-11-01 | |
| Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) Tisagenlecleucel - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2022-01-31 | 2022-03-02 | |
| Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-10-29 | 2024-01-12 | |
| POLA+BR for Relapsed or Refractory DLBCL Polatuzumab Vedotin - Diffuse Large B Cell Lymphoma | Phase 2 | Withdrawn | University of Colorado, Denver | 2021-01-29 | 2022-05-09 | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Selinexor, Rituximab, Bendamustine - Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Karyopharm Therapeutics Inc | 2020-11-18 | 2025-10-03 | |
| Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Bortezomib, Rituximab, Venetoclax - High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma | Phase 2 | Withdrawn | Rutgers, The State University of New Jersey | 2020-05-06 | 2026-01-30 | |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 | |
| A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Pembrolizumab and CXD101 - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | University College, London | 2019-10-01 | 2021-08-17 | |
| Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma Methotrexate, Cytarabine - Diffuse Large B Cell Lymphoma | Phase 2 | Withdrawn | Brown University | 2019-07-01 | 2020-04-13 | |
| Durvalumab in DLBCL After Autologous Transplant Durvalumab - Lymphoma, Large B-Cell, Diffuse | Phase 2 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2017-10-01 | 2018-04-09 | |
| Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Palifermin, Panobinostat, Gemcitabine - Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2017-06-01 | 2017-04-21 | |
| Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) MDV9300 - Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | Medivation, Inc. | 2016-12-01 | 2016-11-25 | |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma Gallium citrate - Lymphoma, Large B-Cell, Diffuse, Burkitt Lymphoma | Phase 2 | Withdrawn | University of California, San Francisco | 2016-06-13 | 2019-10-10 | |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Brentuximab, Bendamustine, Rituximab - Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | University of Arizona | 2015-12-16 | 2017-05-19 | |
| Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma ABC294640 - Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | Phase 1 / Phase 2 | Withdrawn | RedHill Biopharma Limited | 2014-07-01 | 2017-12-07 | |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) bendamustine, navitoclax, rituximab - Diffuse Large B-Cell Lymphoma | Phase 2 | Withdrawn | Genentech, Inc. | 2011-10-01 | 2016-11-02 |
Showing 20 of 36. Sign in to see all of them.
Lymphoma (14) · Burkitt Lymphoma (13) · Lymphoma, Non-Hodgkin (13) · Lymphoma, Follicular (12) · Lymphoma, Mantle-Cell (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Large-Cell, Immunoblastic (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Recurrence (6) · Waldenstrom Macroglobulinemia (6) · Hodgkin Disease (5) · Congenital Abnormalities (4) · Intraocular Lymphoma (4)
Hemic and Lymphatic Diseases (36) · Immune System Diseases (36) · Immunoproliferative Disorders (36) · Lymphatic Diseases (36) · Neoplasms (36) · Neoplasms by Histologic Type (36) · Lymphoproliferative Disorders (34) · Lymphoma, B-Cell (32) · Lymphoma, Non-Hodgkin (23) · Lymphoma (22) · Disease Attributes (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · DNA Virus Infections (14) · Herpesviridae Infections (14)
Rituximab (15) · Cyclophosphamide (8) · Etoposide (8) · Filgrastim (6) · Doxorubicin (5) · Prednisone (5) · Vincristine (5) · Cytarabine (4) · Peripheral Blood Stem Cell Transplantation (4) · Radiotherapy (4) · Bendamustine Hydrochloride (3) · Busulfan (3) · CT-P10 (3) · Dexamethasone (3) · Gemcitabine (3)
M.D. Anderson Cancer Center (4) · University of California, San Francisco (2) · AIDS Malignancy Consortium (1) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Brown University (1) · Cancer Research UK (1) · Fondazione Italiana Linfomi - ETS (1) · Fox Chase Cancer Center (1) · Genentech, Inc. (1) · Gilead Sciences (1) · Hoag Memorial Hospital Presbyterian (1) · Insel Gruppe AG, University Hospital Bern (1) · Karyopharm Therapeutics Inc (1) · La Jolla Pharmaceutical Company (1)
United States (19) · Italy (1) · United Kingdom (1)
Adam J Olszewski, MD (1) · Alexandra M. Levine, MD (1) · Anil Tulpule, MD (1) · Brad Haverkos (1) · Daniel J. Weisdorf, MD (1) · Daniel O. Persky, MD (1) · Dipenkumar Modi, M.D. (1) · Elizabeth Maher, MD, PhD (1) · Graham Collins (1) · Grzegorz Nowakowski (1) · Hector A Preti, M.D. (1) · Jorge Cortes, MD (1) · Katy Rezvani (1) · Kristie A. Blum, MD (1)
P30CA072720 (2), P30CA015083 (1), P30CA016672 (1), P30CA046934 (1)